Published in J Neurol Neurosurg Psychiatry on January 01, 2005
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.13
Prevalence and factors associated with thriving in older adulthood: a 10-year population-based study. J Gerontol A Biol Sci Med Sci (2008) 1.08
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol (2014) 1.04
The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes (2008) 1.03
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes (2006) 1.01
Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. Pharmacoeconomics (2007) 0.94
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One (2013) 0.93
Alcohol use patterns and trajectories of health-related quality of life in middle-aged and older adults: a 14-year population-based study. J Stud Alcohol Drugs (2012) 0.92
Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can (2017) 0.87
Structural equation modeling of factors contributing to quality of life in Japanese patients with multiple sclerosis. BMC Neurol (2013) 0.83
Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health Qual Life Outcomes (2006) 0.82
Quality of life, disability, well-being, and coping strategies in patients undergoing neurosurgical procedures: preoperative results in an Italian sample. ScientificWorldJournal (2014) 0.81
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler (2016) 0.80
Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness. Int Psychogeriatr (2014) 0.80
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology (2016) 0.79
Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis. Health Qual Life Outcomes (2014) 0.79
Early exercise after spinal cord injury ('Switch-On'): study protocol for a randomised controlled trial. Trials (2015) 0.78
Estimating typical multiple sclerosis disability progression speed from clinical observations. PLoS One (2014) 0.76
Generic Preference-based Measures for Low Back Pain: Which of Them Should Be Used? Spine (Phila Pa 1976) (2016) 0.75
Preference-based Health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes (2013) 0.75
Seeking the Balance between Harm and Benefit: The Role of Pharmacosurveillance in Choosing the Drugs We Should Take. Healthc Policy (2011) 0.75
Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex. J Res Pharm Pract (2016) 0.75
Multiple Sclerosis Patients Valuing Their Own Health Status: Valuation and Psychometric Properties of the 15D. Neurol Int (2016) 0.75
Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs (2017) 0.75
Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog). Funct Neurol (2013) 0.75
An initial validation of the Italian Mishel Uncertainty Illness Scale (MUIS) for relapsing remitting multiple sclerosis patients. Neurol Sci (2014) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Measuring health-related quality of life. Ann Intern Med (1993) 11.84
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res (1995) 6.97
Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol (1998) 3.57
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol (1998) 3.55
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51
A health-related quality of life measure for multiple sclerosis. Qual Life Res (1995) 3.46
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med (1983) 2.93
Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics (1995) 2.79
A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med (2001) 2.53
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Adaptation and scale of reference bias in self-assessments of quality of life. J Health Econ (2000) 1.69
Measuring health outcomes. BMJ (1996) 1.49
Cost and health related quality of life consequences of multiple sclerosis. Mult Scler (2000) 1.35
Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil (2001) 1.31
Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil (1988) 1.28
Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry (2000) 1.10
The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry (2001) 1.06
NHS to fund treatment for 10000 patients with MS. BMJ (2002) 1.03
Preference-based quality-of-life in patients with Parkinson's disease. Neurology (2002) 0.98
Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics (2000) 0.97
Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler (2000) 0.96
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care (2000) 0.95
Quality of life in multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 0.91
Health-related quality-of-life assessment and planning for the pharmaceutical industry. Clin Ther (1997) 0.80
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci (1994) 3.53
THE RELATIVE PREVALENCE OF BACTERIA IN AN IMHOFF TANK. Am J Public Health (N Y) (1923) 3.40
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology (2007) 3.17
Educating future physicians for Ontario. Acad Med (1998) 3.06
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 2.59
Dr Samuel Johnson's movement disorder. Br Med J (1979) 2.51
On the death of house officers. Ann Intern Med (1998) 2.34
Major depression in multiple sclerosis: a population-based perspective. Neurology (2003) 2.09
Is Angelman syndrome an alternate result of del(15)(q11q13)? Am J Med Genet (1987) 2.03
Visual acuity and contrast sensitivity in multiple sclerosis--hidden visual loss: an auxiliary diagnostic test. Brain (1977) 2.01
Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci (1993) 1.87
Patterns of cannabis use among patients with multiple sclerosis. Neurology (2004) 1.78
Intrachromosomal gene mapping in man: assignment of nucleoside phosphorylase to region 14cen leads to 14q21 by interspecific hybridization of cells with a t(X;14) (p22;q21) translocation. Somatic Cell Genet (1976) 1.68
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology (2004) 1.66
The restless leg syndrome. Can Med Assoc J (1967) 1.62
Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci (2003) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific regions, extent of deletions, parental origin, and clinical consequences. Am J Med Genet (1990) 1.53
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler (2009) 1.52
Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr (1987) 1.48
Water at hydrophobic surfaces: weak hydrogen bonding and strong orientation effects. Science (2001) 1.48
Use of ophthalmologic services by diabetic patients in Nova Scotia. Can J Ophthalmol (1993) 1.47
A population-based study of multiple sclerosis in twins: update. Ann Neurol (1993) 1.46
Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain (1994) 1.42
Characteristics of patients found not to have multiple sclerosis. Can Med Assoc J (1984) 1.42
Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother (1995) 1.41
Persistent transport barrier on the West Florida Shelf. Geophys Res Lett (2006) 1.40
Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest (1994) 1.39
Relevance in undergraduate neurological teaching. Can J Neurol Sci (1977) 1.38
Treatment of essential tremor with propranolol. Can Med Assoc J (1972) 1.36
Tandem duplication of proximal 22q: a cause of cat-eye syndrome. Am J Med Genet (1985) 1.33
A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci (1992) 1.32
Inflamed solitary caecal diverticulum - it is not appendicitis, what should I do? Ann R Coll Surg Engl (2006) 1.30
Gene dose effect: intraband mapping of the LDH A locus using cells from four individuals with different interstitial deletions of 11p. Cytogenet Cell Genet (1977) 1.27
A poison education program for primary school. Vet Hum Toxicol (1984) 1.27
Characterization of nonfimbrial mannose-resistant protein hemagglutinins of two Escherichia coli strains isolated from infants with enteritis. Infect Immun (1984) 1.27
Auditory brainstem responses in postconcussion syndrome. Arch Neurol (1981) 1.26
Origin of a small metacentric chromosome: familial and cytogenic evidence. Clin Genet (1975) 1.25
Concepts in undergraduate neurological teaching. Clin Neurol Neurosurg (1977) 1.24
Congenital sensory neuropathy. Brain (1973) 1.21
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler (2007) 1.18
Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci U S A (1998) 1.18
DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood (1998) 1.16
Educating future physicians for Ontario: phase II. Acad Med (2000) 1.15
Turner syndrome resulting from partial deletion of Y chromosome short arm: localization of male determinants. J Pediatr (1984) 1.15
Development of intra-natural killer complex (NKC) recombinant and congenic mouse strains for mapping and functional analysis of NK cell regulatory loci. Immunogenetics (1999) 1.14
Complexation-induced unfolding of heterocyclic ureas. Simple foldamers equilibrate with multiply hydrogen-bonded sheetlike structures. J Am Chem Soc (2001) 1.14
Hepatitis B prenatal screening survey, Nova Scotia, 1990-1991. Can J Public Health (1993) 1.12
Quantifying hydrogen bond cooperativity in water: VRT spectroscopy of the water tetramer. Science (1996) 1.12
Wheelchair-related accidents caused by tips and falls among noninstitutionalized users of manually propelled wheelchairs in Nova Scotia. Am J Phys Med Rehabil (1994) 1.09
Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci (1985) 1.07
Spectroscopic determination of the water pair potential. Science (1999) 1.07
Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler (2000) 1.07
Immediate chromosome diagnosis on bone marrow cells: an aid to management of the malformed newborn infant. J Pediatr (1979) 1.07
Long-term therapy of essential tremor with propranolol. Can Med Assoc J (1976) 1.07
Contrast sensitivity, visual acuity and the discrimination of Snellen letters in multiple sclerosis. Brain (1981) 1.04
Depression in multiple sclerosis. Psychother Psychosom (1997) 1.04
Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med (2000) 1.04
Transformation of Escherichia coli with plasmid deoxyribonucleic acid: calcium-induced binding of deoxyribonucleic acid to whole cells and to isolated membrane fractions. J Bacteriol (1981) 1.02
Short term predictors of unemployment in multiple sclerosis patients. Can J Neurol Sci (2003) 0.99
Simultaneous transformation of Escherichia coli by pairs of compatible and incompatible plasmid DNA molecules. Mol Gen Genet (1979) 0.99
Resolution of breakpoints in a complex rearrangement by use of multiple staining techniques: confirmation of suspected 12p12.3 intraband by deletion dosage effect of LDHB. Am J Med Genet (1981) 0.99
Inverted tandem ("mirror") duplications in human chromosomes: -nv dup 8p, 4q, 22q. Am J Med Genet (1977) 0.99
Presidential Address: XVIII Canadian Congress of Neurological Sciences. The neurologist as educator. Can J Neurol Sci (1983) 0.97
A double-blind trial of patient-controlled nitrous-oxide/oxygen analgesia in myocardial infarction. Lancet (1975) 0.97
A cluster of transcribed sequences between the Pb and Ob genes of the murine major histocompatibility complex. Proc Natl Acad Sci U S A (1991) 0.97
Effect of body temperature on visual evoked potential delay and visual perception in multiple sclerosis. J Neurol Neurosurg Psychiatry (1977) 0.96
De novo partial duplication of 17p [dup(17)(p12----p11.2)]: clinical report. Am J Med Genet (1986) 0.96
Predicting sun spots using a layered perceptron neural network. IEEE Trans Neural Netw (1996) 0.96
Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol (2001) 0.96
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care (2000) 0.95
The role of plasmids in adherence of invasive Escherichia coli to mammalian cells. J Infect Dis (1981) 0.95
Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler (2001) 0.94
The Cmv1 host resistance locus is closely linked to the Ly49 multigene family within the natural killer cell gene complex on mouse chromosome 6. Genomics (1997) 0.94
Hydrogen bond breaking dynamics of the water trimer in the translational and librational band region of liquid water. J Am Chem Soc (2001) 0.94
Day case laparoscopic cholecystectomy is safe and feasible: a case controlled study. Int J Surg (2006) 0.93
Essential tremor. Can Med Assoc J (1981) 0.93
Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther (2002) 0.91
Experimental models of neuroprotection relevant to multiple sclerosis. Neurology (2007) 0.91
Spatial frequency discrimination in normal vision and in patients with multiple sclerosis. Brain (1982) 0.90
The scope of neurologic practice and care in England, Canada, and the United States. Is there a better way? Arch Neurol (1989) 0.90
Validity and reliability of the Medical Outcomes Study Short Form-20 questionnaire as a measure of quality of life in elderly people living at home. Age Ageing (1999) 0.90
Relationship between neurological and urological status in patients with multiple sclerosis. J Urol (1984) 0.90
Laparoscopic 'physiological' antireflux procedure: preliminary results of a prospective symptomatic and objective study. Br J Surg (1995) 0.89
An inhalation exposure chamber designed for animal handling. Lab Anim Sci (1981) 0.89
Orientation-specific losses of contrast sensitivity in multiple sclerosis. Invest Ophthalmol Vis Sci (1980) 0.88
Gall bladder cancer--radical surgery, the key role to improve outcome. Ulster Med J (2002) 0.88
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler (2007) 0.88
Dichotic paradigms in multiple sclerosis. Ear Hear (1984) 0.87
Carbon monoxide poisoning from Sterno. Can Med Assoc J (1978) 0.87
An unusual occurrence of multiple sclerosis in a small rural community. Can J Neurol Sci (1976) 0.87
Parental origin of the extra chromosome in the cat eye syndrome: evidence from heteromorphism and in situ hybridization analysis. Am J Med Genet (1988) 0.86